Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Macular Degeneration Treatment Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The macular degeneration treatment market has experienced rapid expansion in recent years. Projections indicate it will grow from $12.38 billion in 2025 to $13.81 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. This historical growth can be ascribed to several factors, including an aging global population, a rise in the prevalence of age-related macular degeneration, the clinical success of anti-VEGF injections, enhanced ophthalmic diagnostic capabilities, and increasing access to specialized eye care services.
The macular degeneration treatment market is poised for substantial expansion in the coming years. By 2030, its value is projected to reach $20.74 billion, demonstrating a compound annual growth rate (CAGR) of 10.7%. This anticipated growth stems from factors such as an expanding global elderly population, increased investment in advanced retinal therapies, a heightened emphasis on managing early-stage age-related macular degeneration, the wider adoption of gene and regenerative treatments, and greater healthcare expenditure on vision care. Significant trends influencing this period encompass an elevated focus on timely diagnosis and managing disease progression, the increasing use of anti-VEGF therapies, a rising need for treatments aimed at long-term vision preservation, the proliferation of minimally invasive treatment methods, and increased public awareness regarding age-related eye conditions.
Get A Free Sample Report With In-Depth Market Insights:
Macular Degeneration Treatment Market Growth Factors Behind Sustained Expansion
The rising prevalence of retinal disorders is projected to stimulate the growth of the macular degeneration treatment market. These conditions affect essential retinal tissue, impacting how individuals interpret visual information and often leading to impaired or lost vision. For instance, the American Academy of Ophthalmology estimates that by 2050, approximately 7.32 million people in the United States will experience primary open-angle glaucoma, a collective term for various eye disorders, with the highest figures observed in populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The most affected demographic group is Hispanic men. Consequently, the increasing burden of retinal disorders is a significant driver for the expansion of the macular degeneration treatment market.
Macular Degeneration Treatment Market Segment Trends And Revenue Contributors
The macular degeneration treatment market covered in this report is segmented –
1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By Route of Administration: Oral, Injectable, Other Routes of Administration
3) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
Subsegments:
1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments
2) By Intermediate AMD: Regular Disease Monitoring and Imaging Surveillance, Risk-Factor Management and Lifestyle Modification
3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options
Macular Degeneration Treatment Market Industry Trends Fueling Future Revenue Growth
Major companies operating in the macular degeneration treatment market are actively developing biosimilars for age-related macular degeneration (AMD) to broaden access to effective therapies. Biosimilars are biological medical products that are highly similar to an already approved reference product, with no clinically meaningful differences regarding their safety, purity, or potency. For instance, in May 2024, Biocon Biologics Ltd, an Indian-based company, and Samsung Bioepis Co. Ltd, a South Korea-based company, obtained FDA Approvals for Yesafili and Opuviz, two new biosimilars. Both biosimilars function by inhibiting vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel growth in the eye. This action assists in preventing vision loss associated with conditions such as AMD and diabetic retinopathy. The FDA’s approval process encompassed comparative studies demonstrating that Yesafili and Opuviz possess no significant differences in efficacy or safety when compared to Eylea. These studies involved rigorous assessments of the biosimilars’ pharmacokinetics and immunogenicity.
Macular Degeneration Treatment Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the macular degeneration treatment market are F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, Graybug Vision Inc
View The Full Macular Degeneration Treatment Market Report:
Macular Degeneration Treatment Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the macular degeneration treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
